“The company’s 4Q18 results beat our expectations on both the top and  bottom line, due primarily to a strong quarter for dental sales. MLSS is  focused on commercializing its epidural instrument with teaching  hospitals, and we expect sales to begin to ramp up in 2019. Although the  intra-articular and botox injection devices have been put on the  backburner for now, we believe they continue to represent a major  opportunity for the company.”
https://www.smarteranalyst.com/brief/maxim-group-thinks-milestone-scientifics-stock-is-going-to-recover-2/